Research programme: pneumococcal polysaccharide vaccine 24-valent - Sinovac Biotech

Drug Profile

Research programme: pneumococcal polysaccharide vaccine 24-valent - Sinovac Biotech

Alternative Names: 24-valent pneumococcal polysaccharide vaccine - Sinovac Biotech; Pneumococcal 24-valent vaccine - Sinovac Biotech; Pneumococcal polysaccharides vaccine - Sinovac Biotech; PPV - Sinovac Biotech

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sinovac Biotech
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Pneumococcal infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Pneumococcal-infections in China (Parenteral)
  • 21 May 2014 Sinovac Biotech plans a phase I trial for Pneumococcal infections in China
  • 01 May 2014 China FDA approves Clinical Trial Application for 24-valent Pneumococcal polysaccharide vaccine candidates
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top